Assessing the impact of gozetotide in PSMA-positive prostate cancer

Gozetotide is a drug for diagnostic application in adults with prostate cancer. It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify patients for whom PSMA-targeted therapy with (177Lu)lutetium vipivotide tetraxetan ("Lutetium-177" for short) is an option.

Oncologists hesitant to intensify treatment for advanced prostate cancer

oncologynews.com.au - 12/Dec 03:23

A recent study has revealed a significant gap between guidelines and clinical practice in the treatment of metastatic prostate cancer. A survey of...

Some Breast Cancer Patients May Not Need Post-Op Chest Wall Radiation

drugs.com - 18/Dec 11:12

WEDNESDAY, Dec. 18, 2024 -- Radiation therapy for breast cancer comes with a host of side effects, including conditions as serious as heart problems...

CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal

zacks.com - 12/Dec 15:31

Candel stock rallies 68% on meeting the primary goal in a phase III study of CAN-2409 combo therapy compared to SOC radiation therapy for prostate...

Promising New Approach in Treating the Deadliest Brain Cancer

medindia.net - 19/Dec 12:39

New treatment approach with proton beam therapy for glioblastoma improves survival rates and quality of life for older patients.

US FDA grants breakthrough therapy designation to GSK's Jemperli for locally advanced dMMR/MSI─H rectal cancer

pharmabiz.com - 17/Dec 03:57

GSK plc announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Jemperli (dostarlimab) for the...

Plus Therapeutics presents ReSPECT─LM phase 1 trial data for breast cancer patients with leptomeningeal metastases

pharmabiz.com - 20/Dec 12:51

Plus Therapeutics, Inc, a clinical─stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for...

SABCS: Imlunestrant Tied to Improved PFS for ER-Positive, HER2-Negative Breast Cancer With ESR1 Mutations

drugs.com - 12/Dec 16:12

THURSDAY, Dec. 12, 2024 -- For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast...

Machine learning model predicts CDK4/6 inhibitor effectiveness in metastatic breast cancer

news.medical.net - 14/Dec 11:25

A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data in...

Tolebrutinib Designated Breakthrough Therapy by the FDA for Non-Relapsing Secondary Progressive Multiple Sclerosis

drugs.com - 13/Dec 03:12

Paris, December 13, 2024. The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of...

FDA Approves Ensacove (ensartinib) for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

drugs.com - 18/Dec 00:12

On December 18, 2024, the Food and Drug Administration approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with anaplastic...

Rubriques :